Department of Bioinformatics, Alagappa University, Karaikudi, India.
Department of Medicine, Musculoskeletal Disease Center, JLP VA Medical Center, Loma Linda University, Loma Linda, CA, USA.
J Biomol Struct Dyn. 2021 Jul;39(11):4148-4159. doi: 10.1080/07391102.2020.1775122. Epub 2020 Jun 11.
Vitamin D deficiency is one of the common clinical symptoms of severe chronic kidney disease (CKD) patients. Vitamin D receptor (VDR) is a part of the nuclear receptor family exerts vitamin D activation to maintain calcium/phosphorous homeostasis and bone metabolism. The reduction of VDR activity leads to vitamin D deficiency. In this study, we found three potent agonists for VDR protein on the structure and ligand-based screening methods. In the structure-based method, 792 compounds were screened. A 5-point pharmacophore (one hydrogen bond acceptor, two hydrophobic and aromatic rings (AHHRR)) was developed and used to obtain a predictive 3 D-Quantitative structure-activity relationship (QSAR), model. The acquire R and Q values are 0.8676 and 0.8523 respectively. Further, E-pharmacophore based screening, molecular docking (binding affinity), Molecular Mechanics-Generalized Born Surface Area (binding free energy), chemical reactivity (Density Functional Theory (DFT) study) and molecular dynamics (protein-ligand stability) analysis were done. Hence, the computational investigations demonstrate that the identified ligands such as TCM_1875, TCM_1874, and TCM_2868 showed promising agonist effect on VDR protein. Further validation and experiments need to be done to confirm the potency of the identified compounds shortly.Communicated by Ramaswamy H. Sarma.
维生素 D 缺乏是严重慢性肾脏病 (CKD) 患者的常见临床症状之一。维生素 D 受体 (VDR) 是核受体家族的一部分,它发挥维生素 D 的激活作用,以维持钙/磷平衡和骨骼代谢。VDR 活性的降低导致维生素 D 缺乏。在这项研究中,我们在结构和基于配体的筛选方法上发现了三种针对 VDR 蛋白的有效激动剂。在基于结构的方法中,筛选了 792 种化合物。开发了一个 5 点药效团(一个氢键受体、两个疏水性和芳香环 (AHHRR)),并用于获得预测性 3D-定量构效关系 (QSAR) 模型。获得的 R 和 Q 值分别为 0.8676 和 0.8523。此外,还进行了基于 E-药效团的筛选、分子对接(结合亲和力)、分子力学-广义 Born 表面积(结合自由能)、化学反应性(密度泛函理论 (DFT) 研究)和分子动力学(蛋白-配体稳定性)分析。因此,计算研究表明,所鉴定的配体,如 TCM_1875、TCM_1874 和 TCM_2868,对 VDR 蛋白表现出有希望的激动剂作用。需要进一步验证和实验来尽快确认鉴定化合物的效力。由 Ramaswamy H. Sarma 交流。